Inclusion Criteria:

        Previously untreated, histologically proven T-cell Lymphoma (any of the following):

          -  Peripheral T-cell lymphoma Not Otherwise Specified (PTCL NOS)

          -  Systemic Anaplastic large cell lymphoma (ALCL) ALK negative cases only

          -  Angioimmunoblastic T-cell lymphoma

          -  Hepatosplenic gamma/ delta T-cell lymphoma

          -  Enteropathy-associated T-cell lymphoma (EATL)

               -  Bulky stage I not being considered for reduced chemotherapy plus involved field
                  radiotherapy or stage II, III or IV.

               -  Patient is male or female, and ≥18 years of age on the day of signing informed
                  consent.

               -  WHO performance status 0, 1 or 2.

               -  Cross sectional imaging from a baseline contrast enhanced CT should show at least
                  one measurable disease site that is at least 2 cm in longest diameter and
                  measurable in two perpendicular dimensions with or without corresponding
                  Fluorodeoxyglucose(FDG) avid lesions.

               -  Adequate cardiac function; formal assessment of left ventricular ejection
                  fraction is only required if clinically indicated (a baseline echocardiogram
                  should be done for patients with either hypertension, age > 60 years or history
                  of cardiac disease)

               -  Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.0x109/l; white
                  blood cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can
                  be post-transfusion), unless deemed disease related

               -  Adequate renal function: calculated creatinine clearance ≥50ml/minute.

               -  Adequate liver function: serum bilirubin ≤1.5x Upper limit of normal (ULN);
                  Alanine transaminase/Aspartate transaminase (ALT/AST) ≤2.5x ULN; ALP ≤3x ULN (in
                  the absence of liver metastases). If liver metastases are present, ALT, AST or
                  Alkaline phosphatase (ALP) ≤5x ULN are permitted. Isolated hyperbilirubinaemia
                  due to Gilbert's disease is acceptable

               -  Female patient of childbearing potential must have a negative serum or urine
                  β-human chorionic gonadotropin(hCG)pregnancy test at baseline.

               -  Written informed consent must be obtained prior to start of study treatments.
                  Scans and bone marrow biopsies performed within 4 weeks of commencement of
                  therapy will be acceptable provided they have been performed according to study
                  requirements.

               -  Patient agreeable to use contraception for the period of study treatment and up
                  to 12 months after the last dose of study drugs.

        Exclusion Criteria:

          -  Documented or symptomatic central nervous system involvement or leptomeningeal
             disease.

          -  Patients with no measurable disease on the contrast enhanced CT scan at baseline.

          -  Any other clinically significant disease or co-morbidity which may adversely affect
             the safe delivery of treatment within this trial.

          -  Any other malignancies diagnosed or treated within the last 5 years (other than
             curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the
             cervix).

          -  Treatment with another investigational agent within 30 days of commencing study
             treatment.

          -  Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C
             virus, acute or active hepatitis B infection.

          -  Patient is pregnant or breastfeeding, or expecting to conceive or father children
             within one year of finishing study treatment.

          -  Patients with poorly controlled diabetes mellitus

          -  Hypersensitivity or contraindication to any of the study drugs as stated in the
             Summaries of product characteristics(SmPCs)for each of the study drugs. Patients with
             previous cardiac infarct but satisfactory cardiac function may be allowed at the
             discretion of Chief Investigator.